Kura Oncology to Participate in Two Investor Conferences in November
SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
Covered in this story
Analyst targets on Kura Oncology Inc
- Citizens JMP: at $9.83 · target $24 by Oct 2027 · Market Outperform via Investing.com
- UBS: at $10.7 · target $15 by Oct 2027 · Buy via Investing.com
- JPMorgan: at $10.7 · target $30 by Oct 2027 · Overweight via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kura Oncology Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.